Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2009-015407-47 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AUY922 | Experimental |
| |
| Docetaxel or Irinotecan | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AUY922 | Drug | 70mg/m2 |
| |
| Docetaxel |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival | 21 day cycle: treatment until death, lost to follow up or withdrawal |
| Measure | Description | Time Frame |
|---|---|---|
| Estimate of the Overall Survival Treatment Effect to see if there is a difference in treatment effect in patients who receive AUY922 versus patients who receive comparator medications. | 21 day cycle: treatment until death, lost to follow up or withdrawal | |
| Objective Response Rate to see if there is a difference in treatment effect in patients who receive AUY922 versus patients who receive comparator medications. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| USC/Kenneth Norris Comprehensive Cancer Center USC/Norris | Los Angeles | California | 90033 | United States | ||
Not provided
| Label | URL |
|---|---|
| ESMO Abstract | View source |
| Results for CAUY922A2202 can be found on the Novartis Clinical Trial Results website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Docetaxel 75mg/m2 |
|
| Irinotecan | Drug | Iriniotecan 350mg/m2 |
|
| 21 day cycle: treatment until death, lost to follow up or withdrawal |
| Evaluate Safety by measuring cardiac safety, recording Adverse Events (AEs) and tracking the tolerability of AUY922 | 21 day cycle: treatment until death, lost to follow up or withdrawal |
| University of California at Los Angeles Dept. of UCLA (4) |
| Los Angeles |
| California |
| 90095 |
| United States |
| Horizon Oncology Center | Lafayette | Indiana | 47905 | United States |
| The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU | Baltimore | Maryland | 21287-0013 | United States |
| Clinical Research Alliance Dept.ofArenaOncologyAssoc(2) | Lake Success | New York | 11042 | United States |
| Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology | Dallas | Texas | 75246 | United States |
| Tyler Cancer Center Dept.ofTylerCancerCtr. (2) | Tyler | Texas | 75702 | United States |
| Novartis Investigative Site | Adelaide | South Australia | 5000 | Australia |
| Novartis Investigative Site | Montreal | Quebec | H3G 1A4 | Canada |
| Novartis Investigative Site | Bordeaux | 33075 | France |
| Novartis Investigative Site | Lyon | 69373 | France |
| Novartis Investigative Site | Toulouse | 31059 | France |
| Novartis Investigative Site | Erlangen | 91054 | Germany |
| Novartis Investigative Site | Ulm | 89081 | Germany |
| Novartis Investigative Site | Genova | GE | 16132 | Italy |
| Novartis Investigative Site | Modena | MO | 41100 | Italy |
| Novartis Investigative Site | Pisa | PI | 56100 | Italy |
| Novartis Investigative Site | Roma | RM | 00168 | Italy |
| Novartis Investigative Site | Naples | 80131 | Italy |
| Novartis Investigative Site | Utrecht | 3584CX | Netherlands |
| Novartis Investigative Site | Moscow | 115478 | Russia |
| Novartis Investigative Site | Moscow | 129128 | Russia |
| Novartis Investigative Site | Singapore | 169610 | Singapore |
| Novartis Investigative Site | Suwon | Gyeonggi-do | 442-723 | South Korea |
| Novartis Investigative Site | Suwon | Gyeonggi-do | 443-380 | South Korea |
| Novartis Investigative Site | Seoul | Korea | 05505 | South Korea |
| Novartis Investigative Site | Bellinzona | 6500 | Switzerland |
| Novartis Investigative Site | Kuei-Shan Chiang | Taoyuan/ Taiwan ROC | 33305 | Taiwan |
| Novartis Investigative Site | Tainan | 704 | Taiwan |
| Novartis Investigative Site | Taipei | 10048 | Taiwan |
| Novartis Investigative Site | Taipei | Taiwan |
| Novartis Investigative Site | Ankara | 06500 | Turkey (Türkiye) |
| Novartis Investigative Site | Surrey | England | GU2 7XX | United Kingdom |
| Novartis Investigative Site | Sutton | Surrey | SM2 5PT | United Kingdom |
| Novartis Investigative Site | Glasgow | G12 0YN | United Kingdom |
| Novartis Investigative Site | Leicester | LE7 5WW | United Kingdom |
| ID | Term |
|---|---|
| D013274 | Stomach Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C528044 | 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide |
| D000077143 | Docetaxel |
| D000077146 | Irinotecan |
| ID | Term |
|---|---|
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D004224 | Diterpenes |
| D013729 | Terpenes |
| D002166 | Camptothecin |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided